• Home
• About Lipoxen
• Our Technologies
• Pipeline
• Partnering
• Corporate Governance
• Investor Centre
• News
  • Careers
  • FAQ
  • Contact us

Lipoxen's Co-Delivery DNA Vaccine Patent Granted in EU and US

29 June 2009

Improved immune response using ImuXen® liposomal technology

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that it has been granted a new Co-Delivery DNA Vaccine Patent in EU and US for its ImuXen® liposomal technology. The new patent claims that Lipoxen's ImuXen® technology can induce an even further enhanced immune response for vaccine delivery when the DNA and antigen components are combined together into the liposomal delivery system. This new patent is a sequel to Lipoxen's existing patent surrounding ImuXen® where an improved immune response was demonstrated previously when DNA alone was entrapped in the liposome technology.

ImuXen® is based on Lipoxen's proprietary techniques that allow the liposomal entrapment of vaccine materials, resulting in enhanced immune responses while reducing the side effects, a feature of traditional vaccines. Co-Delivery provides a gentle but powerful stimulus to the immune response by combining DNA and protein vaccine materials in liposomes. Co-Delivery emulates the effect of a live virus vaccine by delivering its materials (DNA and protein) to the same cells in the immune system potentially resulting in single shot vaccines, while avoiding the risk of infection inherent in live virus vaccines. It also avoids the use of aluminium, a toxic element widely used in killed or subunit vaccines. Lipoxen's Co-Delivery technology has been adopted in collaborative projects with the world's leading AIDS vaccine organization, International AIDS Vaccine Initiative (IAVI), and PATH's Malaria Vaccine Initiative, involving the National Institutes of Health. Co-Delivery has the potential to provide safer and more effective vaccines against a range of serious diseases that continue to afflict man.

Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "The new patent grant on this novel vaccine system is another significant milestone for Lipoxen and further supports our drive to become a leading innovator in vaccines. We have several collaborations in place with some of the world's leading vaccine companies and further technology evaluation projects underway. We expect this new patent will strengthen our capability to collaborate with partners and we look forward to announcing progress on this front in due course."

For further information: